Skip to content
2000
Volume 23, Issue 1
  • ISSN: 1570-1638
  • E-ISSN: 1875-6220

Abstract

Introduction

Capecitabine is an anticancer antimetabolite of fluorouracil that inhibits cell proliferation and impairs DNA repair in cancer cells. It is given specifically to treat metastatic breast, gastric and colorectal cancers.

Objective

To design, formulate, optimize and evaluate Capecitabine Nanosuspension using the QbD Box-Behnken model.

Methods

Deploying the Box-Behnken Design (BBD) model, Capecitabine nanosuspension was formulated with seventeen runs; the independent variables selected are Pullulan concentration, Poloxamer F407 concentration, and sonication time. The developed nanosuspension was evaluated for particle size, zeta potential, entrapment efficiency, drug release, and anti-cancer effectiveness. Drug-excipient compatibility was assessed using the Fourier transform infrared spectroscopy method. X-ray diffraction studies and differential scanning calorimetry were used to perform and assess the crystalline nature. Additionally, characteristics of the developed nanosuspension were assessed by performing a scanning electron microscopy study.

Results and Discussion

The effect of various factors on key responses, namely particle size, entrapment efficiency, and drug release up to 8 hours, was assessed. A polynomial equation was employed through the analysis to optimize the formulation, considering the significance levels indicated by the p-values. Notably, these variables demonstrated a substantial influence on the responses. The comparison between observed and predicted values revealed a relatively minor variance (85.90, 69.57, and 76.34 for particle size, entrapment efficiency, and percentage drug release at 8 hours, respectively), indicating the model's suitability. The prepared nanosuspension exhibited compatibility with the used excipients, with capecitabine-entrapped nanoparticles uniformly dispersed within the suspending medium.

Conclusion

Developed capecitabine nanosuspension demonstrated better efficacy and effectiveness against gastric cancer, with independent variables like pullulan and poloxamer F207 concentration, along with sonication time, influencing particle size, entrapment efficiency, and drug release.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cddt/10.2174/0115701638371974250606041312
2025-06-13
2026-03-07

  • From This Site

    /content/journals/cddt/10.2174/0115701638371974250606041312
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhangY.B. PanX.F. ChenJ. Combined lifestyle factors, incident cancer, and cancer mortality: A systematic review and meta-analysis of prospective cohort studies.Br. J. Cancer202012271085109310.1038/s41416‑020‑0741‑x 32037402
     [Google Scholar]
  2. ChanuM.T. SinghA.S. Cancer disease and its’ understanding from the ancient knowledge to the modern concept.World J Adv Res Rev202215216917610.30574/wjarr.2022.15.2.0809
     [Google Scholar]
  3. MachlowskaJ. BajJ. SitarzM. MaciejewskiR. SitarzR. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies.Int. J. Mol. Sci.20202111401210.3390/ijms21114012 32512697
     [Google Scholar]
  4. ChenZ. ZhangP. XiH. WeiB. ChenL. TangY. Recent advances in the diagnosis, staging, treatment, and prognosis of advanced gastric cancer: A literature review.Front. Med.20218874483910.3389/fmed.2021.744839 34765619
     [Google Scholar]
  5. YanL. ShenJ. WangJ. YangX. DongS. LuS. Nanoparticle-based drug delivery system: A patient-friendly chemotherapy for oncology.Dose Response2020183155932582093616110.1177/1559325820936161 32699536
     [Google Scholar]
  6. GavasS. QuaziS. KarpińskiT.M. Nanoparticles for cancer therapy: Current progress and challenges.Nanoscale Res. Lett.202116117310.1186/s11671‑021‑03628‑6 34866166
     [Google Scholar]
  7. MaddiboyinaB. Ramaiah, Nakkala RK, Roy H. Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications.Chem. Biol. Drug Des.2023102237739410.1111/cbdd.14230 36916008
     [Google Scholar]
  8. ZhangJ. XieZ. ZhangN. ZhongJ. Nanosuspension drug delivery system: Preparation, characterization, postproduction processing, dosage form, and application.In: Nanostructures for drug delivery.Elsevier201741344310.1016/B978‑0‑323‑46143‑6.00013‑0
     [Google Scholar]
  9. AlzahraniS. Al DoghaitherH. Al-ghafariA. PushparajP. 5 Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).Oncol. Rep.202350417510.3892/or.2023.8612 37594133
     [Google Scholar]
  10. PatelPB PatelMM ChauhanMJ NaiduV Oral suspension of capecitabine.WO Patent 2021033144A12021
  11. KoizumiW. SaigenjiK. UjiieS. TerashimaM. SakataY. TaguchiT. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.Oncology200364323223610.1159/000069313 12697963
     [Google Scholar]
  12. BaekJ.H. KimJ.G. JeonS.B. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.Br. J. Cancer200694101407141110.1038/sj.bjc.6603093 16641916
     [Google Scholar]
  13. KangY.K. KangW.K. ShinD.B. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial.Ann. Oncol.200920466667310.1093/annonc/mdn717 19153121
     [Google Scholar]
  14. ZhangX ZhangZ ChaoWu Nanoscale capecitabine and preparation method thereof.CN Patent 102961342B2014
  15. LeeS.H. KimJ.K. JeeJ.P. JangD.J. ParkY.J. KimJ.E. Quality by Design (QbD) application for the pharmaceutical development process.J. Pharm. Investig.202252664968210.1007/s40005‑022‑00575‑x
     [Google Scholar]
  16. RoyH. NayakB.S. NandiS. In silico; factorial screening and optimization of chitosan based gel for urapidil loaded microparticle using reduced factorial design.Comb. Chem. High Throughput Screen.202023101049106310.2174/1386207323666200628110552 32598248
     [Google Scholar]
  17. JenaB.R. PandaS.P. UmasankarK. Applications of QbD-based software’s in analytical research and development.Curr. Pharm. Anal.202117446147310.2174/1573412916666200108155853
     [Google Scholar]
  18. PorwalO. Box-Behnken Design-based formulation optimization and characterization of spray dried rutin loaded nanosuspension: State of the art.S. Afr. J. Bot.202214980781510.1016/j.sajb.2022.04.028
     [Google Scholar]
  19. AbdullahS. El HadadS. AldahlawiA. The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells.Int. J. Pharm.202261312140610.1016/j.ijpharm.2021.121406 34968681
     [Google Scholar]
  20. DangeY. SalunkheV. HonmaneS. ThorawadeK. Design, development and optimization of 5-fluorouracil nanohydrogel for improved anticancer therapy.Bionanoscience20241421696171410.1007/s12668‑024‑01315‑1
     [Google Scholar]
  21. JenaG.K. PatraC.N. PanigrahiK.C. SrutiJ. PatraP. ParhiR. QbD enabled optimization of solvent shifting method for fabrication of PLGA-based nanoparticles for promising delivery of Capecitabine for antitumor activity.Drug Deliv. Transl. Res.20221261521153910.1007/s13346‑021‑01042‑0 34505271
     [Google Scholar]
  22. HazraA. SanyalD. DeA. ChatterjeeS. ChattopadhyayK. SamantaA. Development and in vitro characterization of capecitabine loaded biopolymeric vehicle for the treatment of colon cancer.J. Appl. Polym. Sci.202213926e5237410.1002/app.52374
     [Google Scholar]
  23. GontijoL.A.P. RaphaelE. FerrariD.P.S. FerrariJ.L. LyonJ.P. SchiavonM.A. pH effect on the synthesis of different size silver nanoparticles evaluated by DLS and their size-dependent antimicrobial activity.Materia2020254e-1284510.1590/s1517‑707620200004.1145
     [Google Scholar]
  24. ShahS. PalA. KaushikV.K. DeviS. Preparation and characterization of venlafaxine hydrochloride‐loaded chitosan nanoparticles and in vitro release of drug.J. Appl. Polym. Sci.200911252876288710.1002/app.29807
     [Google Scholar]
  25. SoroushniaA. GanjiF. Vasheghani-FarahaniE. MobediH. Preparation, optimization, and evaluation of midazolam nanosuspension: Enhanced bioavailability for buccal administration.Prog. Biomater.2021101192810.1007/s40204‑020‑00148‑x 33587239
     [Google Scholar]
  26. SahaP. KathuriaH. PandeyM.M. Nose-to-brain delivery of rotigotine redispersible nanosuspension: In vitro and in vivo characterization.J. Drug Deliv. Sci. Technol.20237910404910.1016/j.jddst.2022.104049
     [Google Scholar]
  27. BoseS. SharmaP. MishraV. Comparative in vitro evaluation of glimepiride containing nanosuspension drug delivery system developed by different techniques.J. Mol. Struct.2021123112992710.1016/j.molstruc.2021.129927
     [Google Scholar]
  28. GaikwadS.S. AvhadR.D. KalkotwarR.S. Formulation, development and in vitro characterization of modified release tablets of capecitabine.Drug Dev. Ind. Pharm.2020461203010.1080/03639045.2019.1698595 31778085
     [Google Scholar]
  29. UllahS. AzadA.K. NawazA. 5-fluorouracil-loaded folic-acid-fabricated chitosan nanoparticles for site-targeted drug delivery cargo.Polymers20221410201010.3390/polym14102010 35631891
     [Google Scholar]
  30. KatakamP. PhalgunaY. HarinarayanaD. Formulation, characterization and in vitro evaluation of capecitabine loaded polycaprolactone-chitosan nanospheres.Bangladesh Pharm J2017171182410.3329/bpj.v17i1.22309
     [Google Scholar]
  31. KadukJ.A. GindhartA.M. BlantonT.N. Powder X-ray diffraction of capecitabine, C15H22FN3O6.Powder Diffr.201934328228310.1017/S0885715619000575
     [Google Scholar]
  32. UpadhyayM. AdenaS.K.R. VardhanH. YadavS.K. MishraB. Development of biopolymers based interpenetrating polymeric network of capecitabine: A drug delivery vehicle to extend the release of the model drug.Int. J. Biol. Macromol.201811590791910.1016/j.ijbiomac.2018.04.123 29705110
     [Google Scholar]
  33. SunS.B. LiuP. ShaoF.M. MiaoQ.L. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.Int. J. Clin. Exp. Med.20158101967019681 26770631
     [Google Scholar]
  34. HattarkiS.A. BogarC. BhatK. Triticum aestivum (wheat grass) exhibited anticancer activity on oral cancer (KB) cell line.Int. J. Pharma Res. Health Sci.2020853220322410.21276/ijprhs.2020.05.01
     [Google Scholar]
  35. ChişM. BonifacioA. SergoV. CăinapC. ChişV. BaiaM. Experimental and theoretical investigations of the chemotherapeutic drug capecitabine.J. Mol. Struct.2022125013157710.1016/j.molstruc.2021.131577
     [Google Scholar]
  36. KarA.K. KarB. MahantiB. KumarC. Method validation of capecitabine In API and pharmaceutical dosage from by UV spectrophotometric method.Asian J. Pharm. Clin. Res.202013519119410.22159/ajpcr.2020.v13i5.36985
     [Google Scholar]
  37. JungS.W. JeongY.I. KimS.H. Characterization of hydrophobized pullulan with various hydrophobicities.Int. J. Pharm.2003254210912110.1016/S0378‑5173(03)00006‑1 12623187
     [Google Scholar]
  38. BhattacharyaS. PageA. ShindeP. Capecitabine loaded potato starch-chitosan nanoparticles: A novel approach for targeted therapy and improved outcomes in aggressive colon cancer.Eur. J. Pharm. Biopharm.202420011432810.1016/j.ejpb.2024.114328 38763329
     [Google Scholar]
  39. RameshY. SarayuB. Hari ChandanaG. NeelimaO. SanaS. Formulation and evaluation of lamivudine nanosuspension.J. Drug Deliv. Ther.2021114-S717710.22270/jddt.v11i4‑S.4961
     [Google Scholar]
  40. ClogstonJ.D. PatriA.K. Zeta potential measurement.Methods Mol. Biol.2011697637010.1007/978‑1‑60327‑198‑1_6 21116954
     [Google Scholar]
  41. PourmadadiM. MalekiM. ShamsabadipouraA. RahdarA. GhotekarS. Advancements in capecitabine-loaded nanocomposites as a cutting-edge cancer therapy-A review.Bionanoscience202414133734510.1007/s12668‑023‑01240‑9
     [Google Scholar]
  42. RanchK.M. MaulviF.A. NaikM.J. KoliA.R. ParikhR.K. ShahD.O. Optimization of a novel in situ gel for sustained ocular drug delivery using Box-Behnken design: In vitro, ex vivo, in vivo and human studies.Int. J. Pharm.201955426427510.1016/j.ijpharm.2018.11.016 30423418
     [Google Scholar]
  43. ReddyK.S.C. BhikshapathiD. Design and optimization of DPC-crosslinked HPβCD nanosponges for entrectinib oral delivery: Formulation, characterization, and pharmacokinetic studies.Future J. Pharm. Sci.202410110110.1186/s43094‑024‑00680‑8
     [Google Scholar]
  44. CunhaS. CostaC.P. MoreiraJ.N. Sousa LoboJ.M. SilvaA.C. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review.Nanomedicine20202810220610.1016/j.nano.2020.102206 32334097
     [Google Scholar]
  45. AlsaidanO.A. PattanayakP. AwasthiA. Quality by design-based optimization of formulation parameters to develop quercetin nanosuspension for improving its biopharmaceutical properties.S. Afr. J. Bot.202214979880610.1016/j.sajb.2022.04.030
     [Google Scholar]
  46. RehmanU. SarfrazR.M. MahmoodA. Ph responsive hydrogels for the delivery of capecitabine: Development, optimization and pharmacokinetic studies.Gels202281277510.3390/gels8120775 36547299
     [Google Scholar]
  47. ShaikS. MaddelaS. NalluriB.N. Development of Capecitabine floating tablet dosage forms for treating stomach cancer.J. Drug Deliv. Ther.2020103-s19920510.22270/jddt.v10i3‑s.4171
     [Google Scholar]
  48. BunaciuA.A. UdriştioiuE. Aboul-EneinH.Y. X-ray diffraction: Instrumentation and applications.Crit. Rev. Anal. Chem.201545428929910.1080/10408347.2014.949616 25831472
     [Google Scholar]
  49. RahimiA.M. NabavizadehF. AshabiG. Probiotic Lactobacillus rhamnosus supplementation improved capecitabine protective effect against gastric cancer growth in male BALB/c mice.Nutr. Cancer202173102089209910.1080/01635581.2020.1832237 33955797
     [Google Scholar]
/content/journals/cddt/10.2174/0115701638371974250606041312
Loading
Formulation, Optimization and Design of Capecitabine Nanosuspension to Enhance the Anti-gastric Cancer Efficacy using Box-Behnken Quality-based Design Study
Current Drug Discovery Technologies 23, e15701638371974 (2026); https://doi.org/10.2174/0115701638371974250606041312
/content/journals/cddt/10.2174/0115701638371974250606041312
/content/journals/cddt/10.2174/0115701638371974250606041312
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bioavailability; Box-behnken; capecitabine; Gastric cancer; nanosuspension; QbD

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test